Compliance and satisfaction with switchig from an immediate-release to sustained-release formulation of valproate in people with epilepsy

Epilepsy and Behavior

Volumn 4, Issue 6, 2003, Pages 710-716

  Doughty, Julie ^a   Baker, Gus A ^b   Jacoby, Ann ^c   Lavaud, Virginia ^d  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d SANOFI   (France)

Author keywords

Antiepileptic medication; Compliance; Patient satisfaction; Sustained release; Valproate

Indexed keywords

DEPAKINE CHRONO; VALPROIC ACID; ANTICONVULSIVE AGENT;

ACNE; ADOLESCENT; ADULT; AGED; AGGRESSION; AGITATION; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DEPRESSION; DIPLOPIA; DIZZINESS; DRUG ERUPTION; DRUG FORMULATION; EPILEPSY; EUROPE; FATIGUE; FEMALE; FREQUENCY ANALYSIS; GINGIVA DISEASE; HAIR LOSS; HAND DISEASE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEMORY DISORDER; MENTAL CONCENTRATION; MOTOR DYSFUNCTION; MOUTH DISEASE; NERVOUSNESS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUESTIONNAIRE; RESTLESSNESS; SEIZURE; SIDE EFFECT; SKIN DISEASE; SLEEP DISORDER; SLURRED SPEECH; SOMNOLENCE; STOMACH DISEASE; SUSTAINED RELEASE FORMULATION; THOUGHT DISORDER; TREATMENT OUTCOME; VISUAL IMPAIRMENT; WEIGHT GAIN; ADAPTIVE BEHAVIOR; CLINICAL TRIAL; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; ONSET AGE; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; SICKNESS IMPACT PROFILE; TIME;

ADAPTATION, PSYCHOLOGICAL; ADOLESCENT; ADULT; AGE OF ONSET; AGED; ANTICONVULSANTS; DELAYED-ACTION PREPARATIONS; DEMOGRAPHY; DRUG ADMINISTRATION SCHEDULE; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUESTIONNAIRES; SEIZURES; SICKNESS IMPACT PROFILE; TIME FACTORS; VALPROIC ACID;

EID: 0347418144     PISSN: 15255050     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yebeh.2003.08.013     Document Type: Article

References (20)

1. Buck D, Jacoby A, Baker GA, Chadwick DW. Factors influencing compliance with antiepileptic drug regimes. Seizure 1997;6: 87-93.
2. Buelow JM, Johnson J. Self-management of epilepsy: a review of the concept, its outcomes. Dis Manage Health Outcomes 2000;8:327-36.
3. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Valinda L, Ouellette RN. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-7.
4. Garnett WR. Antiepileptic drug treatment: outcomes, adherence. Pharmacotherapy 2000;20(8, Pt 2):191-199S.
5. Lannon SL. Using a health promotion model to enhance medication compliance. J Neurosci Nurs 1997;29:170-8.
6. Irving P, Al Dahma A, Srinivasan A, Greenwood R. An audit of admissions of patients with epilepsy to a district general hospital. Seizure 1999;8:166-9.
7. Wright EC. Non-compliance-or how many aunts has Matilda? Lancet 1993;342:909-13.
8. Bayliss EA, Park MK, Westfall JM, Zamorski MA. How can I improve patient adherence to prescribed medication? J Fam Pract 2001;50:303-4.
9. Dilorio C, Henry M. Self-management in persons with epilepsy. J Neurosci Nurs 1995;27:338-43.
10. Pugh CB, Collins RJ, Goode J-VR, Garnett WR. Assessing the spectrum of antiepileptic drug use, compliance in a community setting (abstract). Epilepsia 1998;39:S184.
11. Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav 2002;3:338-42.
12. Davis R, David HP, McTavish D. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994;47:332-7.
13. Löscher W. Valproate: a review of its basic pharmacology after 35 years of clinical use in the pharmacotherapy of epilepsy. CNS Drugs 2002;16:669-94.
14. Perrucca E, Gatti G, Frigo GM, Crema A, Calzetti S, Visintini D. Disposition of sodium valproate in epileptic patients. Br J Clin Pharmacol 1978;5:495-9.
15. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002;16:695-714.
16. Retzow A, Vens-capell B, Wangemann M. Influence of food on the pharmacokinetics of a new multiple unit sustained release sodium valproate formulation. Arzneimittelforschung 1997;47: 1347-50.
17. Roberts D, Easter D, O'Bryan-Tear G. Epilim® Chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers. Biopharm Drug Dispos 1996;17:175-82.
18. Ley P. Improving patients' understanding, recall, satisfaction, compliance. In: Broome AK, editor. Health psychology-processes, applications. London: Chapman Hall; 1987.
19. Baker GA, Jacoby A, Francis P, Chadwick DW. The Liverpool adverse drug events profile. Epilepsia 1995;363:S59.
20. Abbetz L, Jacoby A, Baker GA, McNulty P. Patient based assessments of quality of life in newly diagnosed epilepsy patients: validation of the NEWQOL. Epilepsia 2000;41:1119-28.